⌘K
Loading ticker…
Intellia Therapeutics, Inc · Healthcare · Pharmaceutical Products
As of 2026-06-26, Intellia Therapeutics, Inc (NTLA) has a 3-month relative strength percentile of 77 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 62. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 8.9%, relative volume 1.48×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 77, Market Stance is mixed at 47, A/D rating B
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
NTLA is held by 7 ETFs as of Mar 2026. Top owner: XBI at 0.65% weight, $48M notional. Top 3 carry $130M.
Top 7 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | 0.65% | $48M |
| VTIVanguard Total Stock Market ETF | 0.00% | $47M |
| VBVanguard Small Cap ETF | 0.02% | $35M |
| IWMiShares Russell 2000 ETF | 0.05% | $35M |
| VBKVanguard Small-Cap Growth ETF | 0.05% | $20M |
| VXFVanguard Extended Market ETF | 0.02% | $17M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $2M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NTLA Jan avg: 8.64% median: 5.07% win: 50% σ: 31.21% n: 4 2022-04-12 → 2026-05-29 | NTLA Feb avg: 8.02% median: 1.28% win: 50% σ: 18.38% n: 4 2022-04-12 → 2026-05-29 | NTLA Mar avg: -14.52% median: -10.79% win: 0% σ: 10.58% n: 4 2022-04-12 → 2026-05-29 | NTLA Apr avg: -2.30% median: 1.29% win: 60% σ: 19.54% n: 5 2022-04-12 → 2026-05-29 | NTLA May avg: -5.09% median: -1.30% win: 20% σ: 10.42% n: 5 2022-04-12 → 2026-05-29 | NTLA Jun avg: 15.71% median: 10.81% win: 100% σ: 14.23% n: 4 2022-04-12 → 2026-05-29 (current) | NTLA Jul avg: 17.53% median: 20.60% win: 100% σ: 9.82% n: 4 2022-04-12 → 2026-05-29 | NTLA Aug avg: -8.89% median: -9.36% win: 0% σ: 5.19% n: 4 2022-04-12 → 2026-05-29 | NTLA Sep avg: 5.30% median: -7.62% win: 25% σ: 31.43% n: 4 2022-04-12 → 2026-05-29 | NTLA Oct avg: -21.05% median: -23.85% win: 0% σ: 11.04% n: 4 2022-04-12 → 2026-05-29 | NTLA Nov avg: -0.78% median: 3.67% win: 50% σ: 20.51% n: 4 2022-04-12 → 2026-05-29 | NTLA Dec avg: -13.66% median: -12.68% win: 25% σ: 17.71% n: 4 2022-04-12 → 2026-05-29 |